Equities Analysts Set Expectations for Vericel Q4 Earnings

Vericel Corporation (NASDAQ:VCEL) – Equities research analysts at HC Wainwright raised their Q4 2026 earnings per share (EPS) estimates for Vericel in a research report issued to clients and investors on Friday, July 31st. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $0.50 per share for the quarter, up from their prior estimate of $0.46. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.49 per share. HC Wainwright also issued estimates for Vericel’s Q2 2027 earnings at $0.14 EPS, Q3 2027 earnings at $0.12 EPS and Q4 2027 earnings at $0.52 EPS.

Several other brokerages also recently commented on VCEL. Truist Financial reaffirmed a “buy” rating and set a $58.00 price objective (up from $54.00) on shares of Vericel in a research note on Friday. Weiss Ratings raised Vericel from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday. Canaccord Genuity Group set a $60.00 price target on Vericel in a report on Thursday. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, TD Cowen upped their price target on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $58.40.

Vericel Stock Up 0.2%

Shares of VCEL opened at $46.05 on Monday. The stock has a market capitalization of $2.36 billion, a P/E ratio of 97.98 and a beta of 1.06. Vericel has a twelve month low of $28.95 and a twelve month high of $49.32. The firm has a fifty day simple moving average of $42.18 and a two-hundred day simple moving average of $37.46.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, July 30th. The biotechnology company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The company had revenue of $77.46 million for the quarter, compared to the consensus estimate of $72.70 million. During the same period in the previous year, the firm earned ($0.01) earnings per share. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis.

Insider Activity at Vericel

In other news, insider Jonathan Mark Hopper sold 10,000 shares of Vericel stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $45.00, for a total transaction of $450,000.00. Following the sale, the insider owned 75,753 shares of the company’s stock, valued at approximately $3,408,885. The trade was a 11.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of Vericel stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $44.75, for a total transaction of $223,750.00. Following the sale, the chief financial officer directly owned 16,009 shares in the company, valued at $716,402.75. The trade was a 23.80% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 52,232 shares of company stock valued at $2,304,217. 7.60% of the stock is currently owned by company insiders.

Institutional Trading of Vericel

Several large investors have recently bought and sold shares of VCEL. AQR Capital Management LLC purchased a new position in shares of Vericel during the 1st quarter worth approximately $242,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Vericel by 6.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,445 shares of the biotechnology company’s stock valued at $1,403,000 after purchasing an additional 1,847 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Vericel by 13.6% during the first quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company’s stock valued at $16,576,000 after purchasing an additional 44,333 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Vericel by 9.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,028 shares of the biotechnology company’s stock valued at $5,490,000 after purchasing an additional 10,191 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its stake in Vericel by 5.1% in the second quarter. Qube Research & Technologies Ltd now owns 277,253 shares of the biotechnology company’s stock worth $11,797,000 after purchasing an additional 13,422 shares during the period.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.